Compugen CEO on AI-Driven Target Discovery

Compugen CEO Eran Ophir discussed the company's Unigen engine for end-to-end AI-driven target discovery in immuno-oncology. The platform focuses on identifying first-in-class drug targets at the earliest stage of research and development, a process Compugen has pursued long before AI became a buzzword in biotech.